A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

AIM: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. METHODS: Pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Asia Pac J Clin Oncol
Päätekijät: Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Hotta, Katsuyuki, Ohashi, Kadoaki, Kubo, Toshio, Yoshioka, Hiroshige, Yokoyama, Toshihide, Sone, Naoyuki, Kuyama, Shoichi, Kudo, Kenichiro, Yasugi, Masayuki, Takigawa, Nagio, Oze, Isao, Kiura, Katsuyuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://ncbi.nlm.nih.gov/pubmed/30938103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13147
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia